Contact
searchSearch
HMP Global

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Atopic Dermatitis Topic Center

Featured Article

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
Correlation Between Atopic Dermatitis, Neuropsychiatric Comorbidities in Pediatric Populations
08/26/2022
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
Acupuncture Might Reduce Itching in Patients With Atopic Dermatitis
07/29/2022
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
JAK1 Inhibitor Improves Atopic Dermatitis Symptoms, Even in Nonresponders
07/22/2022
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care

Newsfeed

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
News
Does Age of Disease Onset Affect Atopic Dermatitis Treatment Efficacy?
10/28/2022
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3 data to understand dupilumab's efficacy in adults with moderate to severe atopic dermatitis depending on age of disease onset.
Researchers analyzed phase 3...
10/28/2022
First Report Managed Care
News
Monoclonal Antibody Improved Clinical Symptoms, Quality of Life Among Patients With Atopic Dermatitis
10/13/2022
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a systematic review and meta-analysis to further evaluate the safety and efficacy of dupilumab for adults and children/adolescents with atopic dermatitis.
Researchers conducted a...
10/13/2022
First Report Managed Care
News
Monoclonal Antibody Outperforms Other Treatments in Improving Skin Barrier Function
09/09/2022
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI scores for patients with atopic dermatitis who received either a monoclonal antibody, topical corticosteroids, or cyclosporine.
Study authors reported EASI...
09/09/2022
First Report Managed Care
News
Correlation Between Atopic Dermatitis, Neuropsychiatric Comorbidities in Pediatric Populations
08/26/2022
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the connection between pediatric atopic dermatitis and neuropsychiatric comorbidities such as depression, anxiety, and attention-deficit/hyperactivity disorder and determine more research is needed.
Researchers explored the...
08/26/2022
First Report Managed Care
News
Acupuncture Might Reduce Itching in Patients With Atopic Dermatitis
07/29/2022
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with acupuncture, osteopathic medicine, or no intervention so researchers could study the efficacy and cost effectiveness of both treatments compared to control.
Patients were treated with...
07/29/2022
First Report Managed Care
News
JAK1 Inhibitor Improves Atopic Dermatitis Symptoms, Even in Nonresponders
07/22/2022
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically meaningful improvements in itch and quality of life after treatment with a JAK1 inhibitor.
Participants had clinically...
07/22/2022
First Report Managed Care
News
Using Deep Learning to Measure MS-Specific Brain Damage Beyond Aging
11/11/2024
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in Neurology aimed to differentiate age-related brain changes from multiple sclerosis (MS)-specific neurodegeneration using MRI.
A new study published in...
11/11/2024
First Report Managed Care
News
Adverse Event Data Suggest Selective β1-blockers Pose Asthma Risk
11/11/2024
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and asthma-like adverse events appear to be higher with selective β1-blockers than with nonselective blockers and α- and β-blockers.
The risks of asthma and...
11/11/2024
First Report Managed Care
News
RNAi Therapies Offer New Hope for Patients With Hereditary Transthyretin Amyloidosis
11/08/2024
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based treatments for hereditary transthyretin amyloidosis (ATTR) have shown remarkable promise, offering new hope for patients with this rare but devastating genetic disorder.
RNA interference (RNAi)-based...
11/08/2024
First Report Managed Care
News
Revolutionary Single-Dose Gene Therapy Offers New Hope for Adults with Hemophilia B
11/08/2024
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy for hemophilia B has shown remarkable success in reducing bleeding episodes and improving the quality of life for adult patients, according to a recent international phase III clinical trial.
A groundbreaking gene therapy...
11/08/2024
First Report Managed Care
News
Real-World Evidence Supports Efficacy and Safety of Selexipag in Patients With Pulmonary Arterial Hypertension
11/07/2024
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag effectively improves functional class and risk category outcomes in patients with pulmonary arterial hypertension, regardless of maintenance dose.
Real-world data shows selexipag...
11/07/2024
First Report Managed Care
News
Clinical Predictors of One-Year Seizure Freedom After SLAH
11/06/2024
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of Clinical and Translational Neurology aimed to predict 1-year seizure freedom for patients undergoing stereotactic laser amygdalohippocampotomy (SLAH) for mesial temporal lobe epilepsy (MTLE) using a set of...
A study published in Annals of...
11/06/2024
First Report Managed Care
News
Efficacy and Outcomes of Neoadjuvant Immunotherapy in Lung Cancer
11/05/2024
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies suggests that neoadjuvant chemoimmunotherapy may benefit patients with resectable NSCLC and low tumor PD-L1 levels for event-free survival, showing superior outcomes compared to neoadjuvant chemotherapy.
A meta-analysis of 43 studies...
11/05/2024
First Report Managed Care
News
FDA Grants Accelerated Approval for Asciminib as First-Line Treatment in Ph+CML-CP
11/01/2024
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated approval by the US Food and Drug Administration (FDA) for asciminib, a medication for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+CML-CP).
Novartis received accelerated...
11/01/2024
First Report Managed Care
News
HHS Faces Legal Action From 10 Hospitals Over 2023 Medicare Advantage Rule and Reimbursement Calculations
10/30/2024
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US Department of Health and Human Services (HHS), claiming that they were underpaid Medicare reimbursements for serving low-income patients.
Ten hospitals sued the US...
10/30/2024
First Report Managed Care
News
Impact of Immune Checkpoint Inhibitors on Multiple Sclerosis Treatment Outcomes
10/29/2024
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of multiple sclerosis were rare in patients treated with immune checkpoint inhibitors, according to a study presented at the American Academy of Neurology 2024 Annual Meeting.
Relapses and progression of...
10/29/2024
First Report Managed Care

Advertisement

Advertisement

Advertisement

Recent Content

News
Most Patients Not Satisfied With Atopic Dermatitis Treatment, Study Finds
12/20/2022
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among 2000 adults with moderate-to-severe atopic dermatitis who were treated with topicals, systemic therapies, or biologics.
The study was conducted among...
12/20/2022
First Report Managed Care
News
Cohort Study Gauges Incidence of Cardiovascular Events in Moderate-to-Severe AD
12/08/2022
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the incidence of major adverse cardiovascular events, venous thrombotic events, deep vein thrombosis, and others in patients covered by a California health plan.
Researchers investigated the...
12/08/2022
First Report Managed Care
News
Long-term Systemic Treatment for Atopic Dermatitis Does Not Raise Infection Risk
11/22/2022
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the effects of long-term, continuous dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
A 4-year study revealed the...
11/22/2022
First Report Managed Care
News
Two-Thirds of Children Hospitalized for Atopic Dermatitis Insured by Medicare/Medicaid
11/17/2022
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric hospitalizations for atopic dermatitis predominantly involved children covered by public health plans, findings show.
Between 2012 and 2017, pediatric...
11/17/2022
First Report Managed Care
Headshot of Nikolaos Sideris, Aristotle University, Thessaloniki, Greece
Interview
The Future of Atopic Dermatitis: Comparative Studies, Biomarker Testing
11/01/2022
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD candidate-scientific associate, First Department of Dermatology, Aristotle University Medical School, Thessaloniki, Greece, reviews the current state of practice and research in atopic dermatitis, emphasizing the...
Nikolaos Sideris, MD, PhD...
11/01/2022
First Report Managed Care

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement